NeoGenomics/$NEO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NeoGenomics
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Ticker
$NEO
Sector
Primary listing
Industry
Health Care Providers & Services
Headquarters
Employees
2,200
ISIN
US64049M2098
Website
NeoGenomics Metrics
BasicAdvanced
$924M
-
-$0.61
1.64
-
Price and volume
Market cap
$924M
Beta
1.64
52-week high
$19.12
52-week low
$6.08
Average daily volume
2M
Financial strength
Current ratio
2.052
Quick ratio
1.821
Long term debt to equity
45.096
Total debt to equity
68.085
Interest coverage (TTM)
-10.89%
Profitability
EBITDA (TTM)
0.657
Gross margin (TTM)
44.30%
Net profit margin (TTM)
-11.54%
Operating margin (TTM)
-10.61%
Effective tax rate (TTM)
1.35%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-2.75%
Return on equity (TTM)
-8.57%
Valuation
Price to revenue (TTM)
1.356
Price to book
1.04
Price to tangible book (TTM)
26.96
Price to free cash flow (TTM)
-28.169
Free cash flow yield (TTM)
-3.55%
Free cash flow per share (TTM)
-25.49%
Growth
Revenue change (TTM)
10.10%
Earnings per share change (TTM)
-8.76%
3-year revenue growth (CAGR)
11.43%
10-year revenue growth (CAGR)
22.02%
3-year earnings per share growth (CAGR)
27.67%
10-year earnings per share growth (CAGR)
62.42%
What the Analysts think about NeoGenomics
Analyst ratings (Buy, Hold, Sell) for NeoGenomics stock.
Bulls say / Bears say
NeoGenomics anticipates total revenues between $735 million and $745 million for fiscal year 2025, representing an 11% to 13% increase from the previous year's midpoint guidance of $661 million. (Investing.com)
The company expects a significant jump in adjusted EBITDA, forecasting a range of $55 million to $58 million, which translates to an impressive 43% to 51% growth from the FY 2024 guidance of $38.5 million. (Investing.com)
NeoGenomics aims to serve over 1 million patients annually by 2028, indicating a strong growth trajectory and expanding market reach. (Investing.com)
NeoGenomics reported Q4 revenue of $172 million, missing analysts' estimates of $173.2 million, leading to a stock decline of approximately 15%. (Reuters)
The company forecasts a net loss between $85 million and $76 million for 2025, raising concerns about profitability. (Reuters)
CEO Chris Smith announced his retirement effective April 1, 2025, leading to a notable sell-off and uncertainty about future leadership. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
NeoGenomics Financial Performance
Revenues and expenses
NeoGenomics Earnings Performance
Company profitability
NeoGenomics News
AllArticlesVideos
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
Business Wire·2 weeks ago
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
Business Wire·2 weeks ago
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NeoGenomics stock?
NeoGenomics (NEO) has a market cap of $924M as of July 15, 2025.
What is the P/E ratio for NeoGenomics stock?
The price to earnings (P/E) ratio for NeoGenomics (NEO) stock is 0 as of July 15, 2025.
Does NeoGenomics stock pay dividends?
No, NeoGenomics (NEO) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next NeoGenomics dividend payment date?
NeoGenomics (NEO) stock does not pay dividends to its shareholders.
What is the beta indicator for NeoGenomics?
NeoGenomics (NEO) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.